德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023-01-03 14:10
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab) 2022-12-27 08:30
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma 2022-12-23 08:30
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors 2022-12-09 08:30
Antengene Appoints Amily Zhang as its Chief Medical Officer 2022-12-08 08:30
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer 2022-11-15 16:51
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting 2022-11-11 08:30
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting 2022-11-07 14:38
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China 2022-11-02 20:07
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors 2022-10-31 20:22
Antengene to Host Research and Development Day on November 15th and 17th, 2022 2022-10-27 11:07
Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma 2022-10-21 20:37
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting 2022-10-08 10:43
Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA 2022-09-19 09:34
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence 2022-09-14 08:30
Antengene to Present at Upcoming Industry Conferences 2022-09-09 14:43
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma 2022-09-01 08:30
Antengene Announces Interim 2022 Financial Results and Provides Corporate Update 2022-08-31 08:29
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia 2022-08-16 08:30
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma 2022-08-03 08:30
1 2 3 4 5 9